ReviewExpert opinion on biological therapy2022
Rotavirus vaccines: progress and new developments.
Review in Expert opinion on biological therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Systematic literature review and meta-analysis on the prevalence of rotavirus genotypes in Asia from 2015 to 2021.Human vaccines & immunotherapeutics · 2025Pooled it
- Nanomaterial-based vaccines: An advanced approach against rotavirus: A review article.Human vaccines & immunotherapeutics · 2026Review
- Review
- Review
- Meta-analysis and systematic review: efficacy of probiotics in combination with standard therapies for rotavirus enteritis.Annals of medicine and surgery (2012) · 2026Article
- Quantifying the Impact of Switching From Rotarix to Rotavac Rotavirus Vaccine in Ghana.The Journal of infectious diseases · 2026Article
- A small-molecule HSP90 inhibitor, NVP-HSP990, alleviates rotavirus infection.Journal of virology · 2026Article
- Acute kidney injury and hyponatremia in hospitalized patients with rotavirus infection.PloS one · 2026Article
- Global burden of diarrheal diseases attributable to 13 pathogens in children under five: a comprehensive analysis from GBD 2021.Frontiers in pediatrics · 2026Article
- Reporting quality and risk of bias in randomized controlled trials of rotavirus vaccines.Clinical and experimental vaccine research · 2026Article
- Article
- Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990-2021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021.The Lancet. Infectious diseases · 2025Article
- Development of RT-dPCR method and reference material for rotavirus G3P8 and G9P8.Analytical and bioanalytical chemistry · 2025Article
- Insights into recent advancements in human and animal rotavirus vaccines: Exploring new frontiers.Virologica Sinica · 2025Review
- Geographic disparities impacting oral vaccine performance: Observations and future directions.Clinical and experimental immunology · 2025Review
- The burden and etiologies of diarrhea in Asia and its countries from 1990 to 2021 and the forecast to 2040: analyses informed by the global burden of disease study 2021.Frontiers in public health · 2025Article
- Clinical Severity of Enteric Viruses Detected Using a Quantitative Molecular Assay Compared With Conventional Assays in the Global Enteric Multicenter Study.The Journal of infectious diseases · 2024Article
- Article
- Designing the fusion protein of rotavirus VP8 and hepatitis A virus VP1 and evaluating the immunological response in BALB/c mice.Iranian journal of microbiology · 2024Article
- Genetic characterization of group A rotavirus in children with acute gastroenteritis in Kericho County Referral Hospital, Kenya.The Pan African medical journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
introductionRotavirus is the primary cause of severe acute gastroenteritis among children under the age of five globally, leading to 128,500 to 215,000 vaccine-preventable deaths annually. There are six licensed oral, live-attenuated rotavirus vaccines: four vaccines pre-qualified for global use by WHO, and two country-specific vaccines. Expansion of rotavirus vaccines into national immunization programs worldwide has led to a 59% decrease in rotavirus hospitalizations and 36% decrease in diarrhea deaths due to rotavirus in vaccine-introducing countries. AREAS COVERED: This review describes the current rotavirus vaccines in use, global coverage, vaccine efficacy from clinical trials, and vaccine effectiveness and impact from post-licensure evaluations. Vaccine safety, particularly as it relates to the risk of intussusception, is also summarized. Additionally, an overview of candidate vaccines in the pipeline is provided. EXPERT OPINION: Considerable evidence over the past decade has demonstrated high effectiveness (80-90%) of rotavirus vaccines at preventing severe rotavirus disease in high-income countries, although the effectiveness has been lower (40-70%) in low-to-middle-income countries. Surveillance and research should continue to explore modifiable factors that influence vaccine effectiveness, strengthen data to better evaluate newer rotavirus vaccines, and aid in the development of future vaccines that can overcome the limitations of current vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.